MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-19-2026
SELLAS Life Sciences Group Total Liabilities 2011-2026 | SLS
Annual Total Liabilities SELLAS Life Sciences Group
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 7.47 M | 9.97 M | 14.2 M | 16.1 M | 5.93 M | 18.1 M | 10.5 M | 11.7 M | 31.5 M | 37.2 M | 68.6 M | 43.4 M | 82.1 M | 27.2 M | 20.9 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 82.1 M | 5.93 M | 27 M |
Quarterly Total Liabilities SELLAS Life Sciences Group
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5.92 M | 6.16 M | 7.2 M | 9.97 M | 10.6 M | 12.2 M | 14.8 M | 14.2 M | 11.9 M | 13.7 M | 15.9 M | 16.1 M | 13.4 M | 13.2 M | 17.4 M | 5.93 M | 11.3 M | 10.2 M | 11.8 M | 18.1 M | 18.1 M | 18.1 M | 18.1 M | 10.5 M | 10.5 M | 10.5 M | 10.5 M | 11.7 M | 11.7 M | 11.7 M | 11.7 M | 31.5 M | 31.5 M | 31.5 M | 31.5 M | 11.4 M | 37.2 M | 37.2 M | 37.2 M | 68.6 M | 68.6 M | 68.6 M | 68.6 M | 43.4 M | 43.4 M | 43.4 M | 43.4 M | 82.1 M | 82.1 M | 82.1 M | 82.1 M | 27.2 M | 27.2 M | 27.2 M | 27.2 M | 20.9 M | 20.9 M | 20.9 M | 20.9 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 82.1 M | 5.92 M | 27.1 M |
Total Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
1.98 B | - | 2.43 % | $ 254 M |  Germany |
 |
Acorda Therapeutics
ACOR
|
395 M | - | -24.86 % | $ 820 K |  USA |
 |
Adverum Biotechnologies
ADVM
|
109 M | - | - | $ 86.2 M | USA |
 |
Amgen
AMGN
|
50 B | $ 349.36 | 2.75 % | $ 188 B | USA |
 |
AlloVir
ALVR
|
42.9 M | - | 4.14 % | $ 49.1 M | USA |
 |
Amneal Pharmaceuticals
AMRX
|
3.32 B | $ 12.67 | 2.82 % | $ 3.97 B | USA |
 |
Applied Molecular Transport
AMTI
|
46.6 M | - | - | $ 10.1 M | USA |
 |
Applied Therapeutics
APLT
|
72 M | - | - | $ 8.42 M | USA |
 |
argenx SE
ARGX
|
1.36 B | $ 784.45 | 2.48 % | $ 25 B |  Niderland |
 |
I-Mab
IMAB
|
707 M | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
6.45 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
215 M | - | 2.54 % | $ 160 B |  France |
 |
Arcutis Biotherapeutics
ARQT
|
243 M | $ 24.45 | 5.07 % | $ 3.11 B | USA |
 |
Biophytis SA
BPTS
|
20.4 M | - | -13.47 % | $ 169 M | France |
 |
AVROBIO
AVRO
|
6.35 M | - | 1083.1 % | $ 745 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
7.43 M | - | - | $ 7.46 M |  Israel |
 |
AstraZeneca PLC
AZN
|
65.4 B | - | - | $ 96.9 B |  Britain |
 |
Midatech Pharma plc
MTP
|
6.46 M | - | -18.52 % | $ 27.3 M | Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.16 M | - | -1.52 % | $ 24.7 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
411 M | $ 1.47 | 8.17 % | $ 391 M | Britain |
 |
BeiGene, Ltd.
BGNE
|
3.83 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Alterity Therapeutics Limited
ATHE
|
5.89 M | $ 3.83 | 1.86 % | $ 9.21 B |  Australia |
 |
BioNTech SE
BNTX
|
2.76 B | $ 91.3 | 1.87 % | $ 27.2 B | Germany |
 |
CymaBay Therapeutics
CBAY
|
142 M | - | - | $ 3.45 B | USA |
 |
Advaxis
ADXS
|
7.89 M | - | -9.65 % | $ 45.9 M | USA |
 |
Aytu BioScience
AYTU
|
93.3 M | $ 2.72 | 5.84 % | $ 17.1 M | USA |
 |
Burford Capital Limited
BUR
|
1.45 B | $ 4.59 | 0.88 % | $ 742 M | Britain |
 |
Avid Bioservices
CDMO
|
276 M | - | - | $ 789 M | USA |
 |
Cidara Therapeutics
CDTX
|
51.5 M | - | - | $ 1.41 B | USA |
 |
Институт стволовых клеток человека
ISKJ
|
1.1 B | - | - | - |  Russia |
 |
Cabaletta Bio
CABA
|
53 M | $ 3.07 | - | $ 308 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
3.45 M | $ 3.08 | 1.65 % | $ 6.7 B | Israel |
 |
Checkpoint Therapeutics
CKPT
|
20.1 M | - | - | $ 169 M | USA |
 |
Cerus Corporation
CERS
|
157 M | $ 1.93 | 4.89 % | $ 368 M | USA |
 |
Aeterna Zentaris
AEZS
|
21.9 M | - | 5.93 % | $ 314 M |  Canada |
 |
Checkmate Pharmaceuticals
CMPI
|
9.38 M | - | - | $ 231 M | USA |
 |
AgeX Therapeutics
AGE
|
6.99 M | - | -10.17 % | $ 12.2 K | USA |
 |
Concert Pharmaceuticals
CNCE
|
53.1 M | - | - | $ 401 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
62.5 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
37.2 M | - | - | $ 26.5 M | USA |
 |
CTI BioPharma Corp.
CTIC
|
144 M | - | - | $ 1.2 B | USA |
 |
AIkido Pharma
AIKI
|
43.5 M | - | 1.93 % | $ 17.4 M | USA |
 |
Aptose Biosciences
APTO
|
37.2 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Cyclacel Pharmaceuticals
CYCCP
|
1.34 M | - | -4.36 % | $ 27 M | USA |
 |
Cellectar Biosciences
CLRB
|
5.06 M | $ 2.82 | 2.55 % | $ 7.36 M | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
123 M | - | - | $ 2.18 B | USA |
 |
Akero Therapeutics
AKRO
|
75.8 M | - | - | $ 3.67 B | USA |
 |
Dynavax Technologies Corporation
DVAX
|
389 M | - | - | $ 2.02 B | USA |
 |
CureVac N.V.
CVAC
|
470 M | - | - | $ 867 M | Germany |
 |
Cyclerion Therapeutics
CYCN
|
55.9 M | $ 3.47 | -0.29 % | $ 8.74 M | USA |